Athersys, Inc. (NASDAQ:ATHX) Shares Purchased by Livingston Group Asset Management CO operating as Southport Capital Management

Livingston Group Asset Management CO operating as Southport Capital Management boosted its position in Athersys, Inc. (NASDAQ:ATHX) by 83.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 55,000 shares of the biopharmaceutical company’s stock after purchasing an additional 25,000 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Athersys were worth $68,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. A.R.T. Advisors LLC acquired a new stake in Athersys in the second quarter valued at about $52,000. Cambridge Investment Research Advisors Inc. lifted its position in shares of Athersys by 133.2% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 37,550 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 21,450 shares during the period. Jane Street Group LLC acquired a new stake in shares of Athersys during the 2nd quarter valued at approximately $77,000. HighTower Advisors LLC lifted its position in shares of Athersys by 45.6% during the 2nd quarter. HighTower Advisors LLC now owns 61,452 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 19,252 shares during the period. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Athersys during the 3rd quarter valued at approximately $182,000. Hedge funds and other institutional investors own 21.53% of the company’s stock.

Separately, ValuEngine upgraded shares of Athersys from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $6.92.

ATHX stock opened at $1.28 on Friday. The stock has a market capitalization of $203.67 million, a P/E ratio of -7.11 and a beta of 0.33. Athersys, Inc. has a one year low of $1.16 and a one year high of $2.03. The company has a 50 day moving average price of $1.26 and a two-hundred day moving average price of $1.36.

Athersys (NASDAQ:ATHX) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). The firm had revenue of ($0.36) million during the quarter, compared to analysts’ expectations of $1.51 million. Athersys had a negative net margin of 458.03% and a negative return on equity of 131.22%.

In other Athersys news, COO William Lehmann, Jr. sold 30,000 shares of Athersys stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $1.17, for a total value of $35,100.00. Following the completion of the sale, the chief operating officer now directly owns 499,636 shares of the company’s stock, valued at approximately $584,574.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.31% of the stock is currently owned by insiders.

Athersys Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also: What is diluted earnings per share (Diluted EPS)?

Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.